1-9 of 9
Sandra Van Schaeybroeck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer

Manuela Salvucci, Maximilian L. Würstle, Clare Morgan, Sarah Curry, Mattia Cremona, Andreas U. Lindner, Orna Bacon, Alexa J. Resler, Áine C. Murphy, Robert O'Byrne, Lorna Flanagan, Sonali Dasgupta, Nadege Rice, Camilla Pilati, Elisabeth Zink, Lisa M. Schöller, Sinead Toomey, Mark Lawler, Patrick G. Johnston, Richard Wilson, Sophie Camilleri-Broët, Manuel Salto-Tellez, Deborah A. McNamara, Elaine W. Kay, Pierre Laurent-Puig, Sandra Van Schaeybroeck, Bryan T. Hennessy, Daniel B. Longley, Markus Rehm, Jochen H.M. Prehn
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (5): 1200–1212.
https://doi.org/10.1158/1078-0432.CCR-16-1084
Published: 28 February 2017
View article titled, A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Open the PDF for A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer

Philip D. Dunne, Darragh G. McArt, Conor A. Bradley, Paul G. O'Reilly, Helen L. Barrett, Robert Cummins, Tony O'Grady, Ken Arthur, Maurice B. Loughrey, Wendy L. Allen, Simon S. McDade, David J. Waugh, Peter W. Hamilton, Daniel B. Longley, Elaine W. Kay, Patrick G. Johnston, Mark Lawler, Manuel Salto-Tellez, Sandra Van Schaeybroeck
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16): 4095–4104.
https://doi.org/10.1158/1078-0432.CCR-16-0032
Published: 14 August 2016
View article titled, Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer
Open the PDF for Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer

Philip D. Dunne, Sonali Dasgupta, Jaine K. Blayney, Darragh G. McArt, Keara L. Redmond, Jessica-Anne Weir, Conor A. Bradley, Takehiko Sasazuki, Senji Shirasawa, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Manuel Salto-Tellez, Richard H. Wilson, Patrick G. Johnston, Sandra Van Schaeybroeck
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1): 230–242.
https://doi.org/10.1158/1078-0432.CCR-15-0603
Published: 03 January 2016
View article titled, EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Open the PDF for EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

Robbie Carson, Basak Celtikci, Cathy Fenning, Arman Javadi, Nyree Crawford, Lucia Perez-Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, Sandra Van Schaeybroeck
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3230–3240.
https://doi.org/10.1158/1078-0432.CCR-14-2701
Published: 14 July 2015
View article titled, HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in <em>BRAF</em>-Mutant Colorectal Cancer by Downregulation of c-FLIP<sub>L</sub>
Open the PDF for HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in <em>BRAF</em>-Mutant Colorectal Cancer by Downregulation of c-FLIP<sub>L</sub> in another window
Includes: Supplementary data
Journal Articles

AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer

Philip D. Dunne, Darragh G. McArt, Jaine K. Blayney, Murugan Kalimutho, Samanda Greer, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Maurice Loughrey, Keara Redmond, Daniel B. Longley, Manuel Salto-Tellez, Patrick G. Johnston, Sandra Van Schaeybroeck
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (1): 164–175.
https://doi.org/10.1158/1078-0432.CCR-13-1354
Published: 05 January 2014
View article titled, AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Open the PDF for AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer

Leanne Stevenson, Wendy L. Allen, Richard Turkington, Puthen V. Jithesh, Irina Proutski, Gail Stewart, Heinz-Josef Lenz, Sandra Van Schaeybroeck, Daniel B. Longley, Patrick G. Johnston
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5412–5426.
https://doi.org/10.1158/1078-0432.CCR-12-1780
Published: 30 September 2012
View article titled, Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
Open the PDF for Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer

Donal P. McLornan, Helen L. Barrett, Robert Cummins, Ultan McDermott, Cliona McDowell, Susie J. Conlon, Victoria M. Coyle, Sandra Van Schaeybroeck, Richard Wilson, Elaine W. Kay, Daniel B. Longley, Patrick G. Johnston
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (13): 3442–3451.
https://doi.org/10.1158/1078-0432.CCR-10-0052
Published: 30 June 2010
View article titled, Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer
Open the PDF for Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

Joan N. Kyula, Sandra Van Schaeybroeck, Joanne Doherty, Catherine S. Fenning, Daniel B. Longley, Patrick G. Johnston
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (13): 3378–3389.
https://doi.org/10.1158/1078-0432.CCR-10-0014
Published: 30 June 2010
View article titled, Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer
Open the PDF for Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy

Sandra Van Schaeybroeck, Anthi Karaiskou-McCaul, Donal Kelly, Daniel Longley, Leeona Galligan, Eric Van Cutsem, Patrick Johnston
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (20): 7480–7489.
https://doi.org/10.1158/1078-0432.CCR-05-0328
Published: 20 October 2005
View article titled, Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy
Open the PDF for Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy in another window